First Patient Dosed in Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma
The first patient has been dosed in a Phase 1 trial of P-BCMA-101, a new, more powerful type of CAR T-cell therapy to fight multiple…
Myeloma
Gamida Recruiting Myeloma Patients for Phase 1 Trial of Its Killer Cells-based Therapy
Gamida Cell is enrolling participants in a Phase 1 clinical trial of an immunotherapy for myeloma and non-Hodgkin’s lymphoma that is based on expanding the…
Potential Myeloma Therapy Shows Positive Interim Phase 2 Trial Results, According to Report
Molecular Partners‘ multiple myeloma treatment candidate MP0250 showed positive preliminary safety and effectiveness results in an ongoing Phase 2 clinical study, according to the biopharmaceutical…
Multiple Myeloma Patients Remain On Treatment Far Less than in Clinical Trials, Study Finds
Patients with relapsed or refractory multiple myeloma who are treated with new therapy combinations remain on their treatments far shorter than those participating in clinical…
Empliciti Improves Response to Combo Treatment in Newly Diagnosed Myeloma Patients, Study Finds
Newly diagnosed multiple myeloma patients respond better to treatment when Empliciti (elotuzumab) is added to a combination of Revlimid (lenalidomide) and dexamethasone,…
FDA Extends Xgeva Approval to Include Myeloma Patients with Bone Lesions
The U.S. Food and Drug Administration (FDA) has agreed to extend Xgeva‘s (denosumab) approval to include patients with multiple myeloma who have bone lesions. The…
Dual-targeted CAR T-cell Therapy Shows Promising Anti-tumor Response in Mice
A preclinical study has shown that a new dual-targeting APRIL CAR T-cell therapy appears to be better at eliminating multiple myeloma cells than conventional CAR T-cell…
Janssen and Legend Biotech Joining Forces to Advance Myeloma CAR T-cell Therapy
Janssen Biotech and China’s Legend Biotech are teaming up to continue developing and to market Legend’s CAR T-cell therapy for multiple myeloma. A hot…
BioLineRx Readies Phase 3 Myeloma Trial to Mobilize Stem Cells for Transplant
BioLineRx has launched a Phase 3 trial to assess if adding BL-8040 to standard treatment will improve the outflux of blood stem cells from…
Biomarker Found That Detects Myeloma Patients Who Will Benefit from Stem Cell Transplant
A collaboration between GNS Healthcare and the Multiple Myeloma Research Foundation (MMRF) resulted in the discovery of a biomarker called CHEK1 that detects which…
